Improvement in quality of life after therapy for mycobacterium abscessus group lung infection a prospective cohort study

Annals of the American Thoracic Society

Volumn 13, Issue 1, 2016, Pages 40-48

  Czaja, Christopher A ^a,b   Levin, Adrah R ^a   Cox, Christian W ^c   Vargas, Daniel ^b   Daley, Charles L ^a,b   Cott, Gary R ^a,b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

Nontuberculous mycobacteria; Surgery; Therapeutics; X ray computed tomography

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOXITIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; QUINOLONE DERIVATIVE; STREPTOMYCIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACID FAST BACILLUS SMEAR; AGED; ANTIBIOTIC THERAPY; ARTICLE; ATELECTASIS; ATYPICAL MYCOBACTERIOSIS; BACTERIUM CULTURE; BILOBECTOMY; BRONCHIECTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FOLLOW UP; HUMAN; LINGULECTOMY; LOBECTOMY; LUNG CAVITY; LUNG CLEARANCE; LUNG INFECTION; LUNG RESECTION; MALE; MIXED INFECTION; MYCOBACTERIUM ABSCESSUS GROUP LUNG INFECTION; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM KANSASII; PROSPECTIVE STUDY; PSEUDOMONAS; PSEUDOMONAS INFECTION; QUALITY OF LIFE; SEGMENTECTOMY; SMEAR; SPUTUM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEDGE RESECTION; COMPLICATION; DISEASE MANAGEMENT; ISOLATION AND PURIFICATION; LUNG FUNCTION TEST; MICROBIOLOGY; MIDDLE AGED; MULTIPLE PULMONARY NODULES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; OUTCOME ASSESSMENT; PNEUMONIA, BACTERIAL; PROCEDURES; PSYCHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE PULMONARY NODULES; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONECTOMY; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84989193869     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201508-529OC     Document Type: Article

References (33)

1. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993;147:1271-1278.
2. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, et al.; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-834.
3. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185: 881-886.
4. Billinger ME, Olivier KN, Viboud C, de Oca RM, Steiner C, Holland SM, Prevots DR. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis 2009;15:1562-1569.
5. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009;49:e124-e129.
6. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax 2007;62:661-666.
7. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.
8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175: 367-416.
9. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Koh WJ. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.
10. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:565-571.
11. Lyu J, Jang HJ, Song JW, Choi CM, Oh YM, Lee SD, Kim WS, Kim DS, Shim TS. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 2011;105:781-787.
12. Martínez-García MA, Perpiñá-Tordera M, Romá n-Sá nchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739-745.
13. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536-541.
14. Maekawa K, Ito Y, Oga T, Hirai T, Kubo T, Fujita K, Imai S, Niimi A, Chin K, Ichiyama S, et al. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tuberc Lung Dis 2013;17:829-835.
15. Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med 2011; 105:1718-1725.
16. Czaja CA, Levin A, Newell JD, Daley CD, Cott GR. Baseline disease severity and quality of life measurements among subjects with Mycobacterium abscessus chronic pneumonia enrolled in a prospective cohort study of treatment response. Poster presentation at American Thoracic Society conference. May 16, 2011, Denver, CO.
17. Czaja CA, Levin A, Daley CD, Newell JD, Cott GR. Improvement in quality of life during the first six months of therapy for Mycobacterium abscessus complex pulmonary infection. Poster presentation at Infectious Diseases Society of America conference. October 22, 2011, Boston, MA.
18. Czaja CA, Levin AR, Cox CW, Daley CL, Cott GR. Impact of adjunctive lung resection for treatment of M. abscessus complex pneumonia on quality of life (QOL) at 12 months.Poster presentation at Infectious Diseases Society of America conference. October 5, 2013, San Francisco, CA.
19. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, et al.; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14.
20. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M; Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006;61:627-635.
21. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.
22. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85:25-31. [Discussion, p. 33-37].
23. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2:75-79.
24. Martínez-García MA, Perpiñá-Tordera M, Romá n-Sá nchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006;100:1623-1632.
25. Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJ, O'Dochartaigh C, van Haren EH, Vidal LO, Welte T, et al.; B-305 Study Investigators. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014;69: 1073-1079.
26. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189: 975-982.
27. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-499.
28. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251-1259.
29. Calverley PMA. Minimal clinically important difference-exacerbations of COPD. COPD 2005;2:143-148.
30. Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015;70:12-20.
31. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135:1610-1618.
32. Kim HS, Lee KS, Koh WJ, Jeon K, Lee EJ, Kang H, Ahn J. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012;263:260-270.
33. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53:1367-1376.